Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Reexamination Certificate
2006-02-21
2006-02-21
Harris, Alana M. (Department: 1642)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
C424S193100, C424S195110, C424S282100, C424S277100, C424S278100, C424S280100, C514S023000, C514S025000
Reexamination Certificate
active
07001601
ABSTRACT:
This invention provides a vaccine for stimulating or enhancing in a subject to which the vaccine is administered, production of an antibody which recognizes a ganglioside, comprising an amount of ganglioside or oligosaccharide portion thereof conjugated to an immunogenic protein effective to stimulate or enhance antibody production in the subject, an effective amount of adjuvant and a pharmaceutically acceptable vehicle.
REFERENCES:
patent: 4356170 (1982-10-01), Jennings et al.
patent: 4557931 (1985-12-01), Irie et al.
patent: 4591552 (1986-05-01), Neurath
patent: 4652629 (1987-03-01), Patrick et al.
patent: 5102663 (1992-04-01), Livingston et al.
patent: 5256409 (1993-10-01), Blincko
patent: 5344870 (1994-09-01), Ratcliffe et al.
patent: 5599914 (1997-02-01), Wiegand et al.
patent: 5616477 (1997-04-01), Price
J.A. Parsons (Ed.) “Peptide Hormones”, see Chpt. 1, pp 1-7 Jun. 1976.
Burgess et al. J. Cell Biol. 111:2129-38 Nov. 1990.
Lazar et al. Mol. Cell Biol. 8(3):1247-52 (Mar. 1988).
Sallgoller et al. Cancer Immunol. Immune 39:105-116 1994.
Cohen et al. Science 262:841-843 Nov. 1993.
Herbert et al, The Dictionary of Immunologyy 4thEd., Academic Press San Diego CA, 1995 p 163.
Uemura et al., J. Biochem 795 1253-1261, 1976.
Lane et al., J of Biochemical Chemistry, 249 (14): 4460-4466, 1974.
Curti, B.D., Central Revision Oncology/Hematology, 1993:14:29-39.
Diatlovitskaia, E.V. et al, biokhimiia, 56(3): 560-564, 1991; Abstract only.
Ritter, G. et al. Immunobiology, 182(1): 32-43, 1990; Abstract only.
Tsuchida, Journal of the National Cancer Institute, 78: 45-54, 1987.
Livingston, Proc. Natl. Acad. Sci, USA, 84: 2911-2915, 1987.
Fung P.Y.S. et al., “Active Specific Immunotherapy of a Murine Adenocarcinoma Using a Synthetic Tunor-Associated Glycoconjugate”, Cancer Research, Jul. 15, 1990, dol. 50, pp. 4308-4314 (Exhibit 4).
Kensil R.C., et al., “Seperation and Characterization od Saponins With Adjuvant Activity fromQuillaja SaponariaMolina Cortex”The Journal of Immnologyl, Jan. 15, 1991, vol. 146, No. 2, pp. 431-437 (Exhibit 5).
Livingston P.O., et al., “Characterization of IgG and IgM Antibodies Induced in Melanoma Patients by Immunization with Purified GM2Ganglioside”, Cancer Research, Dec. 15, 1989, vol. 49, pp. 7045-7050 (Exhibit 6).
Livingston P.O., et al., “Studies on the Immunogenicity of Synthetic and Natural Thomsen-Friedhenreich (TF) Antigens in Mice: Augmentation of the Response by Quil A and SAF-m Adjuvants and Analysis of the Specificity of the Responses”, Vaccine Research, vol. 1, No. 2, 1992, pp. 99-109 (Exhibit 7).
MacLean G.D et al., “Immunization of Breast Cancer Patients Using a Synthetic Sialyl-Tn Glycoconjugate Plus Detox Adjuvant”, Cancer Immunol. Immunother., vol. 36, 1993, pp. 215-222 (Exhibit 8).
MacLean G.D., et al., “Active Immunization of Human Ovarian Cancer Patients Against a Common Carcinoma (Thomsen-Friedenreich) Determinant Using a Synthetic Carbohydrate Antigen”, Journal of Immunotherapy, vol 11, 1992, pp. 292-305 (Exhibit 9).
Marciani D.J., et al., “Genetically-engineered Subunit Vaccine Against Feline Leukaemia Virus: Protective Immune Response in Cats”, Vaccine, vol 9, Feb. 1991, pp. 89-96 (Exhibit 10).
Newman J.M., et al., “Saponin Adjuvant Induction of Ovalbumin-Specific CD830Cytotoxic T Lymphocyte Responses”, The Journal of Immunology, vol. 148, No. 8, Apr. 15, 1992, pp. 2357-2362 (Exhibit 11).
Ritter G., et al., “Ganglioside Antigens Expressed by Human Cancer Cells”, Seminars in Cancer Biology, vol. 2, 1991, pp. 401-409 (Exhibit 12).
Ritter G., et al., “Antibody Response to Immunization with Purified GD3 Ganglioside and GD3 Derivatives (Lactones, Amide and Gangliosidol) in the Mouse”, Immunobiol., 1990, vol. 182 pp. 32-43 (Exhibit 13).
Wu J-Y. et al., “Saponin Adjuvant Enhancement of Antigen-Specific Immune Responses to an Experimental HIV-1 Vaccine”, The Journal of Immunology, vol. 148, 1992, pp. 1519-1525 (Exhibit 14).
Helling, F., et al. “Increased immunogenicity of GM2 conjugated with KLH and used with adjuvants in patients with melanoma.” Mar. 1993Proceedings Of The 84th Annual Meeting Of The American Association For Cancer Research34: 491, Mar. 1993.
Helling, F., et al. “Construction of immunogenic GD-3 conjugate vaccines.” Aug. 1993Annals Of The New York Academy Of Sciences690: 396-397.
Helling, F., et al. “GD-3 vaccines for melanoma superior immunogenicity of key hole limpet hemocyanin conjugate.” 1994Cancer Research 54: 197-203.
Bystryn, J-C, “Tumor vaccines.” 1990 Cancer And Metastasis Reviews, 9: 81-91.
Ritter, G., et al. “Antibody response to immunization with ganglioside GD3 and GD3 congeners (lactones, amide and gangliosidol) in patients with malignant melignant melanoma.” 1991,Int. J. Cancer48: 379-385.
Fiume, L. et al., Critical Reviews in Therapeutic Drug Carrier Systems, 4(4): 265-284, 1988 (Exhibit 4).
Helling Friedhelm
Livingston Philip Ordway
Cooper & Dunham LLP
Harris Alana M.
Holleran Anne L.
Sloan-Kettering Institute for Cancer Research
White, Esq. John P.
LandOfFree
Ganglioside-KLH conjugate vaccine plus QS-21 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ganglioside-KLH conjugate vaccine plus QS-21, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ganglioside-KLH conjugate vaccine plus QS-21 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3682669